Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected Cohort in Northern South Africa: A pilot study

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 11403-11415

  Masebe, Tracy ^a   Bessong, Pascal Obong ^a   Ndip, Roland Ndip ^b,c   Meyer, Debra ^d  

^a UNIVERSITY OF VENDA   (South Africa)

^b UNIVERSITY OF BUEA   (Cameroon)

^c UNIVERSITY OF FORT HARE   (South Africa)

^d UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

APOC3; Genetic variants; Highly active antiretroviral therapy; HLA B; Lipid disorders; South Africa

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN C3; GENOMIC DNA; HLA B ANTIGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; STAVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ; TENOFOVIR PLUS LAMIVUDINE PLUS DIDANOSINE; TENOFOVIR PLUS LAMIVUDINE PLUS LOPINAVIR; TENOFOVIR PLUS LAMIVUDINE PLUS RITONAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE PLUS DIDANOSINE PLUS LOPINAVIR; ZIDOVUDINE PLUS DIDANOSINE PLUS RITONAVIR; APOLIPOPROTEIN C;

ADULT; ALLELE; APOLIPOPROTEIN C3 PROMOTER GENE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; FEMALE; GENDER; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HEART FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOCOMPATIBILITY GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN LEUKOCYTE ANTIGEN B GENE; HYPERLACTATEMIA; HYPERSENSITIVITY; IMMUNOLOGICAL PARAMETERS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA; VIRUS LOAD; ADOLESCENT; GENETICS; MIDDLE AGED; PROMOTER REGION;

ADOLESCENT; ADULT; APOLIPOPROTEINS C; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SOUTH AFRICA;

EID: 84903388418     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150711403     Document Type: Article

References (39)

1. Tarr, P. E.; Telenti, A. Toxicogenetics of antiretroviral therapy: Genetic factors that contribute to metabolic complications. Antivir. Ther. 2007, 12, 999-1013.
2. Poma, B. Z.; Riva, A.; Nasi, M.; Cicconi, P.; Brogini, V.; Lepri, A. C.; Mologni, D.; Mazzota, F.; Monorte, A.; Mussini, C.; et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008, 22, 1769-1778.
3. Martin, A.; Emery, S. Metabolic disorders and cardiovascular consequences of HIV infection and antiretroviral infection. Expert Rev. Clin. Pharmacol. 2009, 2, 381-390.
4. Marx, B.; Sherer, R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin. Infect. Dis. 2000, 30, S96-S116.
5. Pirmohamed, M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. APPS J. 2006, 8, E20-E26.
6. Mahungu, T. W.; Johnson, M. A.; Owen, A.; Back, D. J. The impact of pharmacogenetics on HIV therapy. Int. J. STD AIDS 2009, 20, 145-151.
7. Tozzi, V. Pharmacogenetics of antiretrovirals. Antivir. Res. 2010, 85, 190-200.
8. Guettier, J. M.; Georgopoulos, A.; Tsai, M. Y.; Radha, V.; Shanthirani, S.; Deepa, R.; Gross, M.; Rao, G.; Mohan, V. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J. Clin. Endocrinol. Metab. 2005, 90, 1705-1711.
9. Clarke, H.; Mousa, S. A. The implications of pharmacogenomics in the treatment of HIV-1 infected patients of African descents. Pharmacogenomics Pers. Med. 2009, 2, 93-99.
10. Tarr, P. E.; Taffe, P.; Bleiber, G.; Furrer, H.; Rotger, M.; Martinez, R.; Hirschel, B.; Battegay, M.; Weber, R.; Vernazza, P.; et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 2005, 191, 1419-1426.
11. Groenendijk, M.; Cantor, R. M.; Blom, N. H.; Rotter, J. I.; de Bruin, T. W.; Dallinga-Thie, G. M. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. J. Lipid Res. 1999, 40, 1036-1044.
12. Green, M. L. Evaluation and management of dyslipidemia in patients with HIV infection. J. Gen. Intern. Med. 2002, 17, 707-810.
13. Bonnet, E.; Ruidavets, J.; Tuech, J.; Ferrieres, J.; Collet, X.; Fauvel, J.; Massip, P.; Perret, B. Apolipoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy. J. Clin. Endocrinol. Metab. 2005, 86, 296-302.
14. Tarr, P. E.; Rotger, M.; Telenti, A. Pharmacogenetics of dyslipidemia in HIV: Candidate gene studies of dyslipidemia in HIV-infected individuals. Pharmacogenomics 2010, 11, 587-594.
15. Boettiger, D. The Clinical Utility of Pharmacogenetic Tests is HIV Therapy. Available online: http://www. google. ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCsQFjAA&url=h ttp%3a%2f%2fdspace. library. uu. nl%2fbitstream%2fhandle%2f1874%2f203507%2fPharmacogen etics_of_HIV_Antiretrovirals_-_Edited_VI%255B1%255D. doc%3fsequence%3d1&ei=CJ5LU_f7EsfmywOe14LYDg&usg=AFQjCNEUkyLNx5mNXEOLOVnAU4BAvNmNVA&sig2=IuGTz lA4IdVWyjoEgH07pQ&bvm=bv. 64542518, d. bGE&cad=rjt (accessed on 14 April 2014).
16. Telenti, A. Pharmacogenomics in HIV disease. In Pharmacogenomics and Personalized Medicine; Cohen, N., Ed.; Humana Press: New York, NY, USA, 2008; pp. 395-412.
17. Lucas, A.; Nolan, D.; Mallal, S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 2007, 59, 591-593.
18. Rodriguez-Novoa, S.; Garcia-Gasco, P.; Blanco, F.; Gonzalez-Pardo, G.; Castellares, C.; Moreno, V.; Jimenez-Nacher, I.; Gonzalez-Lahoz, J.; Soriano, V. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res. Hum. Retroviruses 2007, 23, 1374-1376.
19. Mallal, S.; Phillips, E.; Carosi, G.; Molina, J.; Workman, C.; Tomazic, J.; Jagel-Guedes, E.; Rugina, S.; Kozyrev, O.; Cid, J. F.; et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 2008, 358, 568-579.
20. Foulkes, A. S.; Wohl, D. A.; Frank, I.; Puleo, E.; Restine, S.; Wolfe, M. L.; Dube, M. P.; Tebas, P.; Reilly, M. P. Associations among race/ethnicity, APOC-III genotypes, and lipids in HIV-1 infected individuals on antiretroviral therapy. PLoS Med. 2006, 3, 337-347.
21. Fauvel, J. B.; Bonnet, E.; Ruidavets, J.; Ferrieres, J.; Toffoletti, A.; Massip, P.; Periet, B. An interaction between APOC-III variants and protease inhibitors contributes to high triglyceride/low HDL level in treated HIV patients. AIDS 2001, 15, 2397-2406.
22. Waterworth, D. M.; Talmud, P. J.; Humphries, S. E.; Wicks, P. D.; Sagnella, G. A.; Strazzullo, P.; Alberti, K. G.; Cook, D. G.; Cappuccio, F. P. Variable effects of the APOC3-482C>T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia 2001, 44, 245-248.
23. Miller, M.; Rhyne, J.; Chen, H.; Beach, V.; Ericson, R.; Luthra, K.; Dwivedi, M.; Misra, A. APOC3 promoter polymorphisms C-482T and T-455C are associated with metabolic syndrome. Arch. Med. Res. 2007, 38, 444-451.
24. Hegele, R. A.; Ban, M. R.; Carrington, C. V.; Ramdath, D.; Dan, D. Allele frequencies for candidate genes in atherosclerosis and diabetes among Trinidadian neonates. Hum. Biol. 2001, 73, 525-531.
25. Olivieri, O.; Martinelli, N.; Sandri, M.; Bassi, A.; Guarini, P.; Trabetti, E.; Pissolo, F.; Girelli, D.; Friso, S.; Pignatti, P. F.; et al. Apolipoprotein C-III n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455 APOC3 gene polymorphism in heart disease patients: Example of gene-diet interaction. Clin. Chem. 2005, 51, 360-367.
26. Petersen, K. F.; Dufour, S.; Hariri, A.; Nelson-Williams, C.; Foo, J. N.; Zhang, X.; Dziura, J.; Lifton, R. P.; Shulman, G. I. Apolipoprotein C3 gene variants in nonalcoholoc fatty liver disease. N. Engl. J. Med. 2010, 362, 1082-1089.
27. Yu, J.; Wang, H.; Yang, S.; Yuan, J.; Chen, L.; Chen, C. L.; Huang, D. F.; Wang, Y.; Ju, S. Q.; Zhu, J. The Effect of APOC3 promoter polymorphisms on the risk of hypertriglyceridemia in chinese han population with or without type 2 diabetes mellitus. Lab Med. 2010, 41, 34-39.
28. Williams, F.; Meenagh, A.; Darke, C.; Acosta, A.; Daar, A. S.; Gorodezky, C.; Hammond, E.; Nascimento, E.; Middleton, S. Analysis of the distribution of HLA-B alleles in populations from five continents. Hum. Immunol. 2001, 62, 645-650.
29. Luo, M.; Embree, J.; Ramdahin, S.; Ndinya-Achola, J.; Njenga, S.; Bwayo, J. B.; Pan, S.; Mao, X.; Cheang, M.; Stuart, T.; et al. HLA-A and HLA-B in Kenya, Africa: Allele frequencies and identification of HLA-B*1567 and HLA-B*4426. Tissue Antigens 2002, 59, 370-380.
30. Paximadis, M.; Mathebula, T. Y.; Gentle, N. L.; Vardas, E.; Colvin, M.; Gray, C. M.; Tiemessen C. T.; Puren, A. Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population. Hum. Immunol. 2012, 73, 80-92.
31. Ellis, J. M.; Mack, S. J.; Leke, R. F.; Quakyi, I.; Johnson, A. H.; Hurley, C. K. Diversity is demonstrated in class I HLA-A and HLA-B alleles in Cameroon, Africa: Description of HLA-A*03012, *2612, *3006 and HLA-B*1403, *4016, *4703. Tissue Antigens 2000, 56, 291-302.
32. Tian, W.; Boggs, D. A.; Uko, G.; Essiet, A.; Inyama, M.; Banjoko, B.; Adewole, T.; Ding, W. Z.; Mohseni, M.; Fritz, R.; et al. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes Immun. 2003, 4, 500-505.
33. Adams, S. D.; Barracchini, K. C.; Chen, D.; Robbins, F.; Wang, L.; Larsen, P.; Luhm, R.; Stroncek, D. F. Ambiguous allele combinations in HLA Class I and Class II sequence-based typing: When precise nucleotide sequencing leads to imprecise allele identification. J. Transl. Med. 2004, 2, 30.
34. Hughes, D. A.; Vilar, F. J.; Alfirevic, A.; Pirmohamed, M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004, 14, 335-342.
35. Zucman, D.; Truchis, P.; Majerholc, C.; Stegman, S.; Caillat-Zucman, S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 2007, 45, 1-3.
36. Teslovich, T. M.; Musunuru, K.; Smith, A. V.; Edmondson, A. C.; Stylianou, I. M.; Koseki, M.; Pirruccello, J. P.; Ripatti, S.; Chasman, D. I.; Willer, C. J.; et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2007, 466, 707-713.
37. Masebe, T. M.; Bessong, P. O.; Nwobegahay, J.; Ndip, R. N.; Meyer, D. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients. Dis. Markers 2012, 32, 43-50.
38. BioEdit Programme. Available online: http://www. mbio. ncsu. edu/BioEdit/bioedit. html (accessed on 14 April 2014).
39. Hardy-Weinberg Equilibrium. Available online: http://www. tufts. edu/~mcourt01/Documents/Court%20lab%20-%20HW%20calculator. xls (accessed on 14 April 2014).